Prestige Consumer Healthcare (FRA:PBV) YoY EBITDA Growth : 132.34% (As of Mar. 2024)

View and export this data going back to 2005. Start your Free Trial

What is Prestige Consumer Healthcare YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Prestige Consumer Healthcare's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 132.34%.

Prestige Consumer Healthcare's EBITDA per Share for the three months ended in Mar. 2024 was €1.65.

Prestige Consumer Healthcare YoY EBITDA Growth Historical Data

The historical data trend for Prestige Consumer Healthcare's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prestige Consumer Healthcare YoY EBITDA Growth Chart

Prestige Consumer Healthcare Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

YoY EBITDA Growth

Get a 7-Day Free Trial

233.47

-6.14

21.96

-97.71

4,563.27

Prestige Consumer Healthcare Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial															-436.01	-2.04	-2.98	-3.11	132.34

Prestige Consumer Healthcare YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Prestige Consumer Healthcare's YoY EBITDA Growth for the fiscal year that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (A: Mar. 2024 )
=	(EBITDA per Share (A: Mar. 2024 )	-	EBITDA per Share (A: Mar. 2023 ))	/	\| EBITDA per Share (A: Mar. 2023 ) \|
=	(6.855	-	0.147)	/	\| 0.147 \|
=	4,563.27 %

Prestige Consumer Healthcare's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(1.654	-	-5.114)	/	\| -5.114 \|
=	132.34 %

Prestige Consumer Healthcare YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Prestige Consumer Healthcare's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Prestige Consumer Healthcare (FRA:PBV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Prestige Consumer Healthcare Inc (FRA:PBV) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

PBH:USA

Address

660 White Plains Road, Tarrytown, NY, USA, 10591

Website

https://www.prestigebrands.com

Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.

Prestige Consumer Healthcare (FRA:PBV) Headlines

No Headlines